Nov 6, 2026 | Compliance, Compliance-based wellness, Department of Health and Human Services (HHS), Department of Labor, MedBen WellLiving, Outcomes-based wellness, Regulatory, Smoking, Treasury Department, Weight loss, Weight management, Wellness, Wellness compliance
Many MedBen clients who offer the compliance-based WellLiving program also incorporate outcome-based incentives for smoking cessation, BMI, and other health standards. The Departments of Labor, Health and Human Services, and the Treasury recently issued new guidance...
Aug 31, 2026 | Diabetes, GLP-1s, Weight loss, Weight loss drugs, Weight management
GLP-1s drop weight, but with a notable side effect: Expanded employer budgets. Weight-loss drugs have led prescription drug growth over the past five years. New data show how sharply GLP-1 weight-loss drugs can increase pharmacy spending. Segal’s Health Plan Cost...
Dec 15, 2025 | GLP-1s, MedBen Rx, Medicaid, Pharmacy, Private employers, Weight loss, Weight loss drugs
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
Nov 3, 2025 | GLP-1s, MedBen Rx, Obesity, Weight loss, Weight loss drugs, Weight management
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...
Mar 11, 2025 | Drug costs, GLP-1s, Health care costs, Ozempic, Pharmacy, Rx Costs, Wegovy, Weight loss, Weight loss drugs, Zepbound
The end of shortages on Ozempic, Wegovy, and other semaglutide injections could place added pressure on self-funded health plans to cover the costs of the high-priced medications. On February 21, the FDA confirmed that the supply of GLP-1 drugs used to treat obesity...
Nov 21, 2024 | Bariatric surgery, GLP-1s, MedBen Rx, Wegovy, Weight loss, Weight loss drugs, Zepbound
Bariatric surgeries to treat obesity dropped 25.6% from 2022 to 2023, while prescriptions for GLP-1 drugs more than doubled during that period, according to a new study of privately insured Americans with obesity. However, those who opt for the surgery are seeing...
